Cubist Pharmaceuticals, Inc.
Cubicin maker reports Q4 full-year 2005 results; full-year loss per share totals 60 cents
Published in Pharma Investments, Ventures and Law Weekly, February 26th, 2006
The increase in revenues was primarily attributable to net sales of Cubicin (daptomycin for injection), which increased 94% compared to 2004 to $113.5 million in 2005.
Net loss for the fourth quarter of 2005 was $6.7 million or $0.12 per share, as compared to $17.7 million, or $0.40 per share for the fourth quarter of 2004. For 2005, net loss was $31.9 million or $0.60 per share as compared to $76.5 million or $1.86 per share in 2004.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- BioSphere Medical, Inc.
Uterine fibroid treatment developer reports 20% revenue growth - Biomira, Inc.
Oncology company arranges $16.1M financing - Celgene Corp.
REVLIMID maker reports record operating performance for 2005 - Covalent Group, Inc.
Clinical trials company announces new business contracts with an aggregate value of $1M - Covance, Inc.
Covance announces record results, raises 2006 EPS target - Diamyd Medical AB
Diabetes therapy developer reports loss per share of SEK0.9 - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
